Glioblastoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy.
|
19190120 |
2009 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor.
|
22162573 |
2012 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme.
|
22020333 |
2012 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Negative control of the HGF/c-MET pathway by TGF-β: a new look at the regulation of stemness in glioblastoma.
|
29238047 |
2017 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, TBMS1 is a promising compound for the treatment of glioblastoma and an inhibitor of MET.
|
31349699 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Previously, it was demonstrated that treatment with cabozantinib (MET/VEGFR2/RET inhibitor) prolonged survival of mice carrying orthotopic patient-derived xenografts (PDX) of the MET-addicted glioblastoma model E98, yet did not prevent development of recurrent and cabozantinib-resistant tumors.
|
28751462 |
2017 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data provide new insights into the potential application of miR-144-3p in GBM therapy by targeting MET and then inhibiting the downstream signaling.
|
26250785 |
2015 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Silencing c-Met decreased anchorage-independent colony formation and increased the survival of mice bearing intracranial GBM xenografts.
|
23359207 |
2013 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Amplified met gene linked to double minutes in human glioblastoma.
|
8280494 |
1993 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results indicate the possible existence of multiple mechanisms of MET activation in glioblastomas and that the activation system of proHGF/SF is important in progression of glioblastomas that express endogenous proHGF/SF and require ligand-dependent MET activation.
|
16106403 |
2006 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Recurrence of GB after chemo-radiation could be associated with a variation in PlGF and MET expression.
|
27566180 |
2016 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
GBM tissues frequently overexpressed MET protein at high levels compared with lower-grade gliomas.
|
28668888 |
2017 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumour exosomes from cells harbouring PTPRZ1-MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma.
|
28504721 |
2017 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
An HGF paracrine environment may enhance glioblastoma growth in vivo but did not indicate sensitivity to MET inhibition.
|
22203985 |
2012 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our studies reveal a novel mechanism to alter the recycling process of MET in glioblastoma cancer cells by promoting the receptor degradation through a proteasome-sensitive and lysosome-dependent pathway through the ligand-independent activation of MET using anti-MET antibodies.
|
30760737 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MET Inhibition Elicits PGC1α-Dependent Metabolic Reprogramming in Glioblastoma.
|
31694905 |
2020 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our results indicated that the level of miR-562 was downregulated in GBM tissues and the expression of c-MET was upregulated in tumors.
|
30613151 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We show that the RTKs MET, EGFR, and PDGFR regulate microRNA-134 (miR-134) in GBM.
|
24440911 |
2014 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Finally, combined treatment with BH3-mimetics and c-MET inhibitors results in significantly smaller tumors than each treatment alone in a PDX model system of glioblastoma.
|
29743557 |
2018 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recurrent MET fusion genes represent a drug target in pediatric glioblastoma.
|
27748748 |
2016 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
H1/pHGFK1 exerts anti-tumoural and radiosensitive activities mainly through the inhibition and reversal of IR-induced MET and ATM-Chk2 axis activities in glioblastoma.
|
29348487 |
2018 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, we showed that PKCδ was aberrantly activated in GBM cells by c-MET, a receptor tyrosine kinase hyperactivated in GBM.
|
26700818 |
2016 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study demonstrates the potential of integrated 11C-MET-PET/MRI for response assessment of GBM and the utility of combined assessment of morphologic and metabolic information with the proposal for assessing relapsed GBM.
|
28258444 |
2017 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We also showed that Wnt/β-catenin signaling activities in GBM are directly modulated by the addition of ligand-mediated MET activation or MET inhibition.
|
23258844 |
2013 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we review findings that associate MET expression and activity with a specific, genetically defined glioblastoma stem cell subtype, and data showing how MET sustains the stem cell phenotype in glioblastoma and other tumors.
|
23695554 |
2013 |